A study to investigate the mass balance recovery and pharmacokinetics of 14C TZP-101.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
6
Quotient Clinical
Nottingham, England, United Kingdom
Pharmacokinetics of total radioactivity in plasma
To determine the pharmacokinetics of total radioactivity in plasma (Cmax, tmax, AUC, t1/2)
Time frame: 6 weeks
Pharmacokinetics of parent TZP-101 in plasma
To determine the pharmacokinetics of parent TZP-101 in plasma (Cmax, tmax, AUC, t1/2)
Time frame: 6 weeks
Total radioactivity in urine and faeces
To determine the Urine and faecal recovery of total radioactivity (Ae, Fe%, CLr)
Time frame: 6 weeks
Total radioactivity in plasma
To determine the Total radioactivity in plasma/total radioactivity in whole blood ratio at selected timepoints
Time frame: 6 weeks
Total radioactivity of parent drug in plasma
To determine the Total radioactivity in plasma/parent drug in plasma ratio for selected PK parameters
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.